Table 7 Studies reporting percutaneous transluminal angioplasty as part of stem cell therapy for diabetic foot ulcers
From: Stem cell therapy for diabetic foot ulcers: a review of preclinical and clinical research
Author | Year | N | Study design | Type of cell | Administration route | Results | Follow-up (months) |
|---|---|---|---|---|---|---|---|
Huang et al. [90] | 2010 | 11 | Prospective, one group: - PTA + SCT | Autologous PB-MSC | Intraarterial and intramuscular | Improvement of: • Ulcer healing 66.7% • Gangrene healing 77.8% • Pain 90.9% • Claudication distance 100% • Cold sensation 100% new vessels (P < 0.05) | 3–12 |
Qin et al. [101] | 2013 | 40 | Prospective, NRS, two groups: - PTA only - PTA + SCT | Allogeneic hUC-MSC | Intraarterial | PTA + SCT group showed better: • ABI (P < 0.05) • Skin temperature (P < 0.05) • Claudication distance (P < 0.05) • Number of new vessels (P < 0.05) | 3 |
Dubsky et al. [75] | 2014 | 84 | Retrospective, NRS, three groups: - PTA only - SCT only - Control (no intervention) | Autologous BM-MSC | Intramuscular | PTA + SCT group showed better: • TcPO2 (P < 0.05) • Amputation-free survival (P < 0.05) SCT group showed better • Wound healing in 3 months (P = 0.032), 6 months (P = 0.005), 12 months (P = 0.0013) | 12 |
Qin et al. [71] | 2016 | 53 | Prospective, NRS, two groups: - PTA only - PTA + SCT | Allogeneic hUC-MSC | Intraarterial and intramuscular | PTA + SCT group showed better: • ABI (P < 0.05) • Skin temperature (P < 0.05) • Claudication distance (P < 0.05) • TcPO2 (P < 0.05) | 1–3 |
Tian et al. [70] | 2016 | 61 | Prospective, RCT, three groups: - PTA only - SCT only - PTA + SCT | Autologous BM-MSC | Intraarterial and intramuscular | PTA + SCT group showed: • Better total effective rate (P < 0.05) • Lower stenosis recurrence (P < 0.05) | 9 |